Production (Stage)
Navco Pharmaceuticals Inc.
NAV.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 98.83% | -395.53% | 55.90% | -47.12% | -120.08% |
| Total Depreciation and Amortization | 0.00% | -98.04% | 27.50% | 146.91% | -1.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.74% | 38,464.29% | -98.31% | 6,253.85% | 100.09% |
| Change in Net Operating Assets | -94.12% | -1.07% | -44.54% | 87.42% | 179.66% |
| Cash from Operations | 96.32% | -2.70% | 53.16% | 63.89% | 67.65% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | 44.39% | -- | -- | -- |
| Total Debt Repaid | 0.00% | -35.14% | 24.49% | 20.97% | 10.14% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -122.36% | 46.36% | 405.56% | 20.00% | 82.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -53.57% | 62.67% | 82.60% | 62.19% | 68.62% |